GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (FRA:MOL) » Definitions » Research & Development

Moleculin Biotech (FRA:MOL) Research & Development : €16.66 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Moleculin Biotech Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Moleculin Biotech's Research & Development for the three months ended in Mar. 2024 was €3.91 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €16.66 Mil.

Moleculin Biotech Research & Development Historical Data

The historical data trend for Moleculin Biotech's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moleculin Biotech Research & Development Chart

Moleculin Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only 9.91 10.49 12.76 17.91 17.87

Moleculin Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.31 3.59 3.07 6.08 3.91

Moleculin Biotech Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €16.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moleculin Biotech  (FRA:MOL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Moleculin Biotech Research & Development Related Terms

Thank you for viewing the detailed overview of Moleculin Biotech's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Moleculin Biotech (FRA:MOL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (FRA:MOL) » Definitions » Research & Development
Comparable Companies
FWPAY APRE TARA ONTX OCEL CALC GOVX VBIV SNSE MLCT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
MBRX:USA MOLA:Germany
Address
5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Website
https://www.moleculin.com
Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.

Moleculin Biotech (FRA:MOL) Headlines

No Headlines